Background: Immune checkpoint inhibitors have improved overall survival rates for many cancers, yet the majority of patients do not respond to treatment and succumb to disease progression. One tumor-related mechanism limiting the efficacy of immunotherapies in melanoma is the recruitment and expansion of myeloidderived suppressor cells (MDSCs). Therefore, targeting MDSCs in combination with immunotherapies is an attractive strategy to improve response rates and effectiveness. Methods: We tested this strategy by designing a randomized phase II clinical trial treating advanced melanoma patients with either Ipilimumab monotherapy or Ipilimumab plus all-trans retinoic acid (ATRA). Clinicaltrails. gov identifier (NCT02403778). The frequency of circulating MDSCs and the activation of CD8(+) T cells was measured by flow cytometry. Expression of immunosuppressive genes was measured with quantitative real time-PCR. T cell suppressive functions were measured by mixed lymphocyte reaction. Results: Here we show that in vitro treatment with ATRA decreases immunosuppressive function of MDSCs in mixed lymphocyte reactions. Additionally, ATRA reduces the expression of immunosuppressive genes including PD-L1, IL-10, and indoleamine 2,3-dioxygenase by MDSCs. Furthermore, the addition of ATRA to standard of care Ipilimumab therapy appears safe, as ATRA did not increase the frequency of grade 3 or 4 adverse events. Finally, ATRA significantly decreased the frequency of circulating MDSCs compared to Ipilimumab treatment alone in advanced-stage melanoma patients. Conclusions: These results illustrate the importance of MDSCs in immunotherapy resistance and provide evidence that targeting MDSCs in cancer patients may augment immunotherapeutic approaches.
Introduction
Ipilimumab, a fully humanized anti-cytotoxic lymphocyte antigen 4 (CTLA-4) antibody, was the first U.S. Food and Drug Administration (FDA) approved therapy to significantly improve overall survival (OS) in advanced melanoma patients [1] and was the vanguard for a new generation of immunotherapies. In clinical trials, Ipilimumab increased median overall survival from 6.4 to 10.1 months in in pre-treated metastatic melanoma patients and, more importantly, demonstrated that a subpopulation of patients experience a durable response [1] . While Ipilimumab has improved the outlook for many melanoma patients, melanoma wields a vast arsenal of resistance mechanisms that decrease https://doi.org/10.1016/j.intimp.2018.08.007 Received 30 April 2018; Received in revised form 24 July 2018; Accepted 6 August 2018 the efficacy of many types of cancer therapies [2] [3] [4] [5] .
Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature immunosuppressive myeloid lineage cells [6] [7] [8] . The frequency of MDSCs is expanded in the spleen, circulation of patients with cancer, and in the tumor microenvironment of a variety of cancers [9] [10] [11] . Notably, increased numbers of circulating MDSCs are correlated with decreased responses to Ipilimumab in melanoma patients [12, 13] . Accumulation of MDSCs in the tumor microenvironment and periphery is driven by tumor-derived factors including chemokines, growth factors, and cytokines [8] . MDSCs promote tumor growth by producing immunosuppressive molecules in the tumor microenvironment such as interleukin-10 (IL-10), transforming growth factor-β (TGFβ), reactive oxygen species (ROS), as well as expressing cell surface receptors that inhibit T cell proliferation and activation, and producing molecules that directly promote tumor growth and invasion such as vascular endothelial growth factor (VEGF) and matrix metalloproteinases (MMPs) [8, 14] . This complex set of immunosuppressive and tumor promotional mechanisms pose a significant obstacle to the successful treatment of melanoma and other cancers. Therefore, targeting MDSCs represents an attractive strategy to improve the effectiveness of existing immunotherapies.
The vitamin A derivative all-trans retinoic acid (ATRA) is the current standard of care therapy for the treatment of acute promyelocytic leukemia (APL) [15] . In APL patients, ATRA terminally differentiates immature myelocytic tumor cells, resulting in death of the tumors cells [16] . Similar to its effects on immature myelocytic tumor cells, ATRA induces the differentiation of MDSCs, resulting in decreased frequencies of MDSCs in the circulation. Although the mechanism of MDSC differentiation following ATRA treatment is still under investigation, ATRA has been shown to decrease both the frequency and function of MDSCs through activation of ERK1/2, upregulation of glutathione synthase, and generation of glutathione [17] . The increased production of glutathione decreased production of ROS and resulted in subsequent terminal differentiation of MDSCs [17] .
ATRA has been combined with other therapies in several clinical trials directly targeting solid tumors [18] [19] [20] [21] , and in two previous clinical trials targeting MDCSs [22, 23] . In the prior MDSC trials, ATRA decreased the frequency of circulating MDSCs in advanced renal cell carcinoma and lung cancer patients when combined with either high dose IL-2 [22] or with a cancer vaccine [23] . Based on these preceding observations, we designed a clinical trial with the goal of reducing the effects of MDSCs in advanced melanoma patients. This trial builds on the success of Ipilimumab by combining it with ATRA to target MDSCs. Patient enrollment in this study was halted due to low enrollment following the approval of anti-PD1 therapies. However, these initial results show that MDSCs can be targeted with ATRA in melanoma patients during immune checkpoint inhibitor therapy.
Methods

Description of patient population and treatment
Patients with stage III or stage IV melanoma were enrolled in this study. The trial was registered at ClinicalTrials.gov, https:// clinicaltrials.gov/ct2/show/NCT02403778, in February 2015 as NCT02403778. All patients provided a written informed consent, and the treatment protocol was approved by Colorado Multiple Institutional Review Board. Patients being considered for treatment with Ipilimumab were consented and randomized to either Ipilimumab alone or combination Ipilimumab plus ATRA. Patients under the age of 18, who received systemic therapy within four weeks prior to beginning this study, women pregnant or nursing, or patients with a contraindication for taking either ATRA or Ipilimumab were excluded from this trial. Based upon these criteria, ten patients were enrolled at the University of Colorado Cancer Center (Aurora, CO) from December 2015 to August 2016 (Table 1) . None of the patients enrolled in this study were previously treated with systemic therapies for their melanoma. Ipilimumab was given according to the standard of care consisting of four adjuvant infusions of 10 mg/kg for stage III patients or four infusions of 3 mg/kg for stage IV patients every three weeks [1, 24] . Of the patients with stage III disease, three received the additional maintenance doses of Ipilimumab, while four did not receive the maintenance doses due to either toxicity or personal choice to end therapy. Patients in the Ipilimumab plus ATRA arm were treated with ATRA at 150 mg/m 2 on the day before, the day of, and the day after Ipilimumab infusion ( Fig. 1 ).
Patients were assigned to treatment groups by random allocation concealment using blinded envelope draw. Progression was determined according to response evaluation criteria in solid tumors (RECIST 1.1) guidelines, as measured by standard of care imaging every three months. Safety was monitored, and adverse events were classified according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. This trial was originally designed to recruit 24 patients into each arm and was powered to test the intended initial intended primary objectives 1) determine the safety and tolerability of Ipilimumab and ATRA combination therapy in advanced melanoma patients, 2) determine if MDSC frequency in peripheral blood of advanced melanoma patients is altered by Ipilimumab and ATRA combination therapy, and 3) determine if Ipilimumab and ATRA alter the suppressive function of peripheral blood MDSCs. The trial was closed to accrual due to low enrollment following the approval of anti-PD1 therapies.
Sample collection
Peripheral blood was collected from each patient into tubes containing acid citrate dextrose anticoagulant (BD Biosciences). Research blood draws were performed at five time points; pre-treatment (0 to 30 days prior to the first Ipilimumab infusion), Draw 2 (day 21), Draw 3 (day 42), Draw 4 (day 63), and post treatment (84-130 days) as illustrated in Fig. 1A . Each research blood draw corresponded with standard of care clinical blood testing including complete blood counts (CBC) with automated differential count.
In vitro MDSC generation and RT-PCR
Human MDSCs were generated by first isolating CD14(+) cells from leukoreduction system chambers collected from normal healthy donors (Bonfils Blood Center) by positive magnetic selection (Miltenyi Biotec). Isolated CD14(+) cells were incubated with 20 ng/mL GM-CSF and 20 ng/mL IL-6 [25] (Biolegend) for five days in RPMI 1640 media (Gibco) supplemented with 10% normal human serum (Gemini Bio Products), 2 mM L-glutamine (Mediatech), 100 μg/mL Streptomycin (Mediatech), 100 IU/mL Penicillin (Mediatech), 25 mM HEPES (Mediatech). Cells were also treated with either 2 μM ATRA or an equivalent volume of dimethyl sulfoxide (Sigma-Aldrich) vehicle. Expression of the MDSC phenotypic markers CD11b, CD14, and CD33 was confirmed by flow cytometry as below (Fig. 3A) . After 96 h of incubation, cells were removed, and RNA was isolated using RNeasy Spin Columns (Qiagen) per the manufacturer's instructions. cDNA was generated using the Versco cDNA Synthesis Kit (Thermo Scientific) per the manufacturer's instructions. Quantitative real-time PCR was performed using the Applied Biosystems Taqman Gene Expression Master Mix assay system with primers for indoleamine 2,3-dioxygenase (IDO), IL10, NADPH oxidase 1 (NOX1), programed death ligand-1 (PDL1), TGFβ, class II major histocompatibility complex transactivator (CIITA), and β-actin (Invitrogen). C t (threshold cycle) values were determined by the Applied Biosystems Step One Plus RealTime PCR System. Data were analyzed by the ΔΔCT method as in [26] .
Flow cytometry
Peripheral blood was collected and plasma was removed after centrifugation at 340 ×g for 10 min, and red blood cells were lysed using BD Pharmlyse (BD Bioscience) per the manufacture's protocol. The remaining white blood cells were then stained using the following fluorescently tagged monoclonal antibodies: APC-Lineage (CD3, CD19, CD20, CD56), BV570-CD45 (clone HI30), BV421-CD11b (clone ICRF44), APC-Cy7-CD14 (clone HCD14), PE-Cy7-CD15 (clone W6D3), FITC-CD33 (clone HIM3-4), PerCP-Cy5.5-HLA-DR (L243) (BioLegend). Live/dead discrimination was performed using Zombie Red dye (Biolegend). Stained cells were analyzed using the Beckman Coulter Gallios flow cytometer at the University of Colorado Cancer Center Flow Cytometry Shared Resource. Data were analyzed using FlowJo software Version 10.2 (Treestar).
T cell suppression assay
The suppressive functions of MDSCs were measured as previously described [11] . Briefly, MDSCs were generated as described above. HLA-DR(+) monocyte-derived dendritic cells were generated by incubating CD14(+) cells, isolated as above, with recombinant human IL-4 (100 ng/mL, Gemini Bioproducts) and GM-CSF (70 ng/mL, Gemini Bioproducts) for 5 days at 37°C in 5% CO 2 in a 24-well plate [27, 28] . Lipopolysaccharide from Escherichia coli 0111:B4 (0.1 μg/mL, SigmaAldrich) was added 24 h prior to T cell stimulation assays. T cells were isolated from the CD14(−) negative fraction of the leukoreduction system chamber by negative magnetic bead isolation (Miltenyi Biotec) and labeled with CFSE (Life Technologies), 1 × 10 5 T cells were stimulated in a mixed lymphocyte reaction (MLR) using allogeneic T cell stimulation with 2 × 10 4 monocyte-derived dendritic cells from healthy donor in the presence of 1 × 10 5 MDSCs previously treated with DMSO (vehicle) or 2 μM ATRA. After four days, the supernatants were removed, and the cells were stained for T cell activation markers and analyzed by flow cytometry. The percentage of divided cells was determined by analyzing the frequency of CD3(+) CD8(+) CFSE(low) cells.
T cell response assay
Peripheral blood mononuclear cells (PBMC) were isolated over a density gradient using Ficoll-Paque Plus (GE Healthcare). Isolated PBMC were washed in phosphate buffered saline and incubated for 5 h with FITC-anti-CD107a (Biolegend) and Protein Transport Inhibitor (eBioscience) in RPMI1640 as above with or without 50 ng/mL phorbol 12-myristate 13-acetate (PMA), and 1 μg/mL ionomycin (SigmaAldrich). After incubation the cells were washed and stained with APCCy7-CD8 (clone HIT8a), PerCP-Cy5.5-CD19 (clone HIB19), PerCPCy5.5-HLA-DR (clone L243), and Zombie Red (Biolegend). The cells were then washed, fixed and permeabilized using the BD Biosience Cytoperm/Cytofix kit per the manufacture's protocol, and stained with BV421-IFNγ (clone 4S.B3, Biolegend). Flow cytometric analysis was analyzed as above. A total of 4 patients from the Ipilimumab only group and 3 from Ipilimumab plus ATRA were included in this analysis. There was insufficient sample from one of the Ipilimumab plus ATRA treated patients and the T cell response assay was not performed.
Multiplex cytokine analysis
The concentrations of IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, IL-13, tumor necrosis factor-α (TNFα), and IFNγ in the plasma were measured using the V-PLEX Proinflammatory Panel 1 Human Kit (Meso Scale Discovery) according to the manufactures protocol. The concentrations of each cytokine were quantified on a QuickPlex SQ 120 instrument (Meso Scale Discovery) located in the Human Immune Monitory Shared Resource at the University of Colorado School of Medicine.
Statistical analysis
Patients who received at least three Ipilimumab infusions and had full data sets were included in the pre vs. post-treatment analysis. The T cell response assay was not performed on the post-treatment sample from one patient in the Ipilimumab plus ATRA treated group due to insufficient cells. All patients were included in the safety analysis. After receiving one dose of the first ATRA cycle, one patient experienced ATRA-related side-effects, most notably headache, resulting in reassignment to the Ipilimumab-only treatment group. The results from this patient were analyzed as part of the Ipilimumab-only group. All graphical and statistical analyses were performed using GraphPad Prism Software (version 6). To confirm that parametric tests are appropriate for this dataset, the distribution was tested using Skewness and Kurtosis tests. All skewness values were between 0.7 and 1.3 with most values falling between 0.95 and 1.05, indicating normal distribution. Group means were compared using parametric paired and unpaired two-tailed Student's t-test for two groups and one-way ANOVA for multiple groups with p values adjusted for multiple comparisons using Tukey's approach. Multiple group means over time were compared using two-way ANOVA with p values adjusted for multiple comparisons using Bonferroni's approach. Correlations were evaluated using Spearman correlation coefficients with p values reported.
Results
The combination of Ipilimumab and ATRA appears to be safe
Adding ATRA to standard of care Ipilimumab in melanoma patients did not increase the number of adverse events (Table 2 ). Due to the relatively high expected adverse event rate observed in Ipilimumab treated patients, and from what has been reported in the literature [24] , it is difficult to specifically identify ATRA-related adverse events as there can be overlap in the general toxicity profiles of the these drugs. One specific ATRA-related side effect, pseudotumor cerebri (intracranial hypertension) was observed in a single patient and resolved after discontinuation of ATRA. Headache (an expected side effect of ATRA) occurred in all patients who received ATRA. As per CTCAE guidelines headache is included in the eye and neurological system disorders section (Table 2) . Though tempered by the limited number of patients treated with ATRA, there were no obvious differences in the frequency of serious adverse events (grade 3 or 4) between the two treatment groups. One patient received a single partial dose of ATRA before switching to the Ipilimumab only group due to severe headaches.
Clinical outcomes
The average follow-up time for the Ipilimumab group was 318 days (248-375, ± 36) and 365 days (322-417, ± 39) for the Ipilimumab plus ATRA group. During this time, two of the six patients in the Ipilimumab-only group have presented with radiological evidence of progressive disease. No patients in the Ipilimumab plus ATRA group have shown evidence of disease progression.
ATRA decreases the expression of immunosuppressive genes in human MDSCs in vitro
MDSCs prevent productive anti-tumor immune responses by producing immunosuppressive molecules including IL-10, indoleamine 2,3-dioxygenase (IDO), TGFβ, and reactive intermediates [8, 14] . To determine if ATRA alters the immunosuppressive capacity of MDSCs, the expression of immunosuppressive genes in cultured human CD14(+) MDSCs was evaluated by real-time PCR after 5 days of treatment with 2 μM ATRA. CD14(+) MDSCs were chosen for these experiments because in vitro-derived monocytic-MDSCs recapitulate the function and phenotype of their in vivo counterparts, while CD15(+) cells do not survive freezing or long periods in culture [9, 29, 30] . We found that ATRA significantly reduced the expression of the immunosuppressive genes NOX1, IL10, TGFβ, IDO, and PDL1 ( Fig. 2A) . Additionally, ATRA increased the expression of the class II, major histocompatibility complex transactivator (CIITA), a positive regulator of HLA-DR expression and a marker of conventional myeloid cells [31, 32] ( Fig. 2A) . To confirm that the changes in gene expression observed in ATRA-treated MDSCs resulted in changes at the protein level we stained ATRA-treated and control cells for HLA-DR and analyzed cell surface expression by flow cytometry. ATRA treatment resulted in increased cell surface expression of HLA-DR compared to vehicle treated cells (Fig. 2B) , indicating a more differentiated and/or activated state. However, ATRA did not alter the cell surface expression of the other MDSC markers CD11b, CD33 or CD14 (Fig. 2C) . We also sought to determine if treatment with ATRA later in MDSC induction would alter the expression of immunosuppressive genes by MDSCs. We found no changes in the expression of immunosuppressive genes or HLA-DR expression by in vitro generated MDSCs treated with 2 μM ATRA at 48 h after induction compared to vehicle treated cells (data not shown).
Additionally, to determine if lower immunosuppressive gene expression and increased HLA-DR expression in ATRA treated MDSCs correlated with decreased T cell suppression, we performed T cell suppression assays. As previously described [33] , pretreating MDSC with ATRA decreases the in vitro T cell suppressive function of MDSCs (Fig. 2D) . 
ATRA reduces the frequency of circulating MDSCs and increases the frequency of HLA-DR(+) myeloid cells in melanoma patients
Increased frequencies of circulating MDSCs correlate with decreased responses to Ipilimumab treatment in melanoma patients [12, 13] . Therefore, we analyzed the frequency of circulating MDSCs after treatment with Ipilimumab alone or in combination with ATRA by flow cytometry (Fig. 3A) . A total of 4 patients in each group received at least three Ipilimumab infusions and provided a sufficient volume of blood to perform these analyses. The frequency of circulating MDSCs (identified as Live CD45(+)Lin(−)CD11b(+)CD33(+)HLA-DR(−) cells (Fig. 3A) was analyzed at each blood draw. This population of cells is highly immunosuppressive and was shown to be decreased by ATRA treatment in two previous clinical trials testing different therapeutic combinations [22, 34] . The frequency of circulating MDSCs was determined over the entire course of treatment to compare the effects between the two treatment groups. We also analyzed the frequency of circulating MDSCs before the beginning of treatment (Pre) and after treatment had concluded (Post). We observed that patients treated with the combination of ATRA and Ipilimumab had decreased frequencies of circulating MDSCs both as a percentage of the myeloid cell population (Fig. 3B and D) and the total CD45(+) population ( Fig. 3C and E) compared to Ipilimumab alone. Additionally, we observed a significant decrease in the frequency of MDSCs as a percentage of the total myeloid cells in the ATRA treated patients, while the frequency of MDSCs increased over time in the patients treated with Ipilimumab alone (Fig. 3B  and D) . We also observed an increase in the frequency of MDSCs as a fraction of the total CD45(+) cells in the Ipilimumab only group and no change in the Ipilimumab plus ATRA group (Fig. 3E) .
In previous studies, ATRA has been shown to differentiate immature immunosuppressive MDSCs into mature HLA-DR expressing myeloid cells. Therefore, we determined the frequency of circulating Lin (−)CD11b(+)HLA-DR(+) cells (Fig. 3A) . We observed a trend towards an increased frequency of circulating HLA-DR(+) myeloid cells over time in the ATRA treated patients compared to Ipilimumab alone (Fig. 3F) . There was an increase in the frequency of HLA-DR+ myeloid cells after ATRA treatment but not in the patients treated with Ipilimumab alone (Fig. 3G) . Additionally, the ratio of MDSCs:HLA-DR(+) myeloid cells decreased after treatment in the Ipilimumab plus ATRA group but not in the Ipilimumab alone group (Fig. 3H) .
The effects of ATRA on CD8+ T cell activation
To determine if a decrease in the frequency of MDSCs were associated with improved CD8+ T cell responses, we performed intracellular cytokine staining to determine the frequency of CD107a(+) IFNγ(+) CD8(+) T cells (Fig. 4A) , molecules that are positively associated with anti-tumor immunity [35, 36] . We found that 3/3 patients treated with the combination therapy, in contrast to only 1/4 patients treated with Ipilimumab alone, had an increased frequency of activated CD107a(+) IFNγ(+) CD8+ T cells after treatment (Fig. 4B) . Overall, there was a trend towards an increase in activated CD107a(+) IFNγ(+) CD8+ T cells in the patients treated with combination therapy (p = 0.1), but not in the patients treated with Ipilimumab alone (p = 0.6) (Fig. 4B) . Importantly, in all samples the frequency of CD107a (+) IFNγ(+) CD8+ T cells inversely correlated with the frequency of circulating MDSCs (Fig. 4C) .
Finally, to determine if ATRA treatment altered the concentrations of circulating immunosuppressive or factors we performed multiplex cytokine array. We measured the plasma concentrations of IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, IL-13, TNFα, and IFNγ. No statistically significant differences were observed between the two arms or between pre-and post-treatment concentrations (Supplementary Fig. 1 ).
ATRA decreases the frequency of circulating eosinophils
As part of standard of care clinical testing, we analyzed CBC data generated by the clinical laboratory. A total of 4 Ipilimumab only and 4 Ipilimumab plus ATRA patients were included in this analysis. There were no significant changes in the frequency of circulating total white cells, neutrophils, or lymphocytes between the two treatment groups (Fig. 5A-D) . However, patients treated with the combination had significantly decreased frequencies of circulating eosinophils compared to patients treated with Ipilimumab alone, as expressed in terms of both absolute number and percentage of total white cells ( Fig. 5E and F ).
Discussion
Previous studies have reported that the frequency of circulating MDSCs negatively correlates with clinical responses to Ipilimumab [11, 12] . Additionally, clinical trials have shown that ATRA can decrease the frequency of circulating MDSCs in cancer patients [22, 23] . Here we show that ATRA decreases the frequency of circulating MDSCs in melanoma patients treated in combination with Ipilimumab.
Similar to previous reports, we show that ATRA decreases the expression of genes associated with the production of ROS in MDSCs including NOX1 [17] . In these studies, decreasing ROS production resulted in diminished immunosuppression and differentiation into normal myeloid cells. There is strong evidence in the literature that MDSCs are associated with decreased efficacy of immunotherapies [12, 13] . We hypothesized that decreasing the frequency of MDSCs with ATRA may improve the efficacy of Ipilimumab.
In this pilot trial, the frequency of circulating MDSCs began decreasing in patients treated with the combination of ATRA and Ipilimumab by the third treatment cycle and continued decreasing through the post-treatment blood draw ( Fig. 3B and C) . The decrease in MDSC frequency was associated with a corresponding increase in the frequency of HLA-DR(+) myeloid cells (Fig. 3F, G, and H) . The small, but statistically significant rise of MDSC frequency in the Ipilimumab only arm was unexpected. Two previous reports regarding the impact of Ipilimumab on the frequency of MDSCs found different results, with one reporting a small decrease in MDSC frequency following Ipilimumab treatment [37] , and the other finding variable results [34] . In both of these reports, and our previous work [11] , the frequency of MDSCs is typically associated with disease burden and severity. There was no significant difference in the pre-treatment frequency of MDSCs between the two treatment groups. Although the frequencies of circulating MDSCs are small compared to their frequencies within tumors [7] , the observed decrease in MDSCs beginning around the third treatment cycle may represent the cumulative effect all of the previous doses of ATRA.
The small number of patients analyzed in this study limits generalized statements regarding T cell function, but there is a trend towards improved T cell responses in the ATRA treated patients. MDSCs inhibit CD8+ T cells via a variety of immunosuppressive pathways [8, 10] and the frequency and phenotype of CD8+ T cells in tumor microenvironment and circulation have been shown to be predictors of responses to immunotherapies [35, [38] [39] [40] . The observed correlation between the frequency of MDSCs and activated CD8+ T cells did reach statistical significance and illustrates the immunosuppressive potency of MDSCs in melanoma patients.
Based on the limited data from this trial, the addition of ATRA to standard of care Ipilimumab appears to be safe. We did not observe an increase in the frequency of serious (grade 3 or 4) adverse events in the patients who received ATRA. All patients who received ATRA experienced headache, an anticipated side effect of ATRA, and resulted in one patient switching to the Ipilimumab only group after taking a partial dose of ATRA. Additionally, one patient presented with ATRA-related pseudotumor cerebri. This patient discontinued treatment with both ATRA and Ipilimumab. Importantly, due to the small sample size, a larger study will be required to definitively test the safety of this combination therapy.
While this study is too small to perform survival analysis, it is worth noting that two of the six patients in the Ipilimumab-only cohort presented with radiographic evidence of progressive disease, while none of the patients in the Ipilimumab plus ATRA group had signs of disease progression. Of the two patients that showed signs of progressive disease both were initially diagnosed with stage III disease.
We found that patients treated with ATRA and Ipilimumab had a significantly lower frequency of eosinophils in the periphery compared to people treated with Ipilimumab alone. This is consistent with previous literature showing that ATRA reduces the expression of IL-5 receptor on eosinophil progenitor cells, resulting in decreased differentiation of eosinophils [41] . There have been few reports in the literature in regard to the impact of eosinophils in patients being treated with Ipilimumab. These studies have shown that an increased frequency of eosinophils during Ipilimumab therapy correlates with improved clinical responses [42, 43] , but also with immune-related adverse events [44] . The effects of eosinophil frequency on clinical outcomes could not be determined in this pilot study due to its limited size, but will be studied in future larger cohorts.
Due to the rapid advancement of anti-PD-1 therapies shortly after the initiation of this trial, patient recruitment to this trial was limited. We expanded patient eligibility to include Stage III patients being treated with Ipilimumab, accepting that the two groups of patients receive different doses of Ipilimumab as standard of care and have different disease burdens. As expected, the 10 mg/kg dose prescribed to the stage III patients is associated with significantly higher frequencies of adverse immunological effects than the 3 mg/kg dose prescribed to the stage IV patients [1, 24] . The improved safety profile and efficacy of anti-PD-1 therapies compared to Ipilimumab [45] led to low recruitment and study was discontinued due to low enrollment. Nonetheless, the results presented here demonstrate the potential safety and efficacy of targeting MDSCs in combination with immunotherapies. Accordingly, we have begun recruiting patients for a follow-up clinical trial combining ATRA with the anti-PD1 antibody Pembrolizumab in stage IV melanoma patients (NCT03200847).
Conclusions
As a proof of concept, this trial shows that ATRA decreased the frequency of MDSCs and did not appear to significantly increase the incidence of grade 3 or 4 adverse events in melanoma patients being treated with Ipilimumab. The decreased frequency of MDSCs was associated with an increased frequency of activated CD8+ T cells and mature HLA-DR(+) myeloid cells. Combining ATRA or other MDSCtargeting agents with immunotherapies represents a promising strategy to improve outcomes in cancer patients.
Supplementary data to this article can be found online at https:// doi.org/10.1016/j.intimp.2018.08.007. All patients were enrolled in accordance with approved protocols, international standards of good clinical practice, and institutional safety monitoring by the Colorado Multiple Institutional Review Board. Written informed consent was provided.
List of abbreviations
Authors' contributions
RPT, KJR, WAR, VFB and MDM conceived and designed the study. RPT and DD performed laboratory correlative experiments. RPT, KJR, WAR, and MDM analyzed and interpreted data. All authors contributed to writing the manuscript and approved the final version of the manuscript.
